When Healthcare Access Becomes an Economic Variable
- 10 hours ago
- 1 min read
How healthcare access influences diagnosis timing, evidence generation, treatment utilization, and downstream healthcare costs
Healthcare costs are rarely measured where they actually start, during the months or years patients spend trying to reach care, only to encounter closed doors, failed referrals, and diagnostic dead ends. By the time a definitive diagnosis is made, disease has progressed, treatment options have narrowed, and utilization has multiplied.
Yet most HEOR models, clinical evidence strategies, and market access frameworks begin measuring costs only after treatment is established. They do not capture the repeated primary care visits, the emergency department trips, the empiric therapies that did not help, or the patients who never entered specialist care at all.
In our latest white paper, Rubix LS examines why healthcare access is an upstream economic variable, not a downstream delivery challenge. The analysis shows how 25.3 million uninsured Americans, 92 million people in primary care shortage areas, and systemic diagnostic delays create costs that conventional evidence frameworks cannot see, price, predict, or prevent. Every invisible patient is a gap in evidence, and every gap in evidence is uncertainty in strategy. For sponsors, payers, and CROs, the patients driving the highest costs are often the ones missing from the models meant to estimate them.
